ArticlePloS one2020
Risk of second primary breast cancer among cancer survivors: Implications for prevention and screening practice.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- Risk of Second Primary Cancers in Melanoma Survivors: A Retrospective Hospital-Based Cohort Study from Two Romanian Referral Centres.Medical sciences (Basel, Switzerland) · 2026Article
- Effects of pomegranate seed extract and ellagic acid on miR-16-5p and miR-34a-5p expression, cell cycle, and apoptosis in MCF-7 cells.Research in pharmaceutical sciences · 2026Article
- Immigration and Social Factors, Tumor Stage, and Risk of Contralateral Breast Cancer in Asian American and Hispanic Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Case report of invasive ductal carcinoma of the breast in a Pakistani male aged 55.Discover oncology · 2026Article
- Reproductive factors and risk of contralateral breast cancer by age and hormone receptor status: The California Breast Cancer Survivorship Consortium.International journal of cancer · 2026Article
- Modifiable and Nonmodifiable Risk Factors for Breast Cancer: A Comprehensive Scoping Review.International journal of breast cancer · 2026Review
- Overall and central adiposity and risk of contralateral breast cancer: The California Breast Cancer Survivorship Consortium.International journal of cancer · 2026Article
- A nomogram for predicting the central lymph node metastasis in double primary carcinoma involving thyroid carcinoma.Gland surgery · 2025Article
- Optimal Surrogate-Assisted Sampling for Cost-Efficient Validation of Electronic Health Record Outcomes.Statistics in medicine · 2025Article
- Risk factors for second primary breast cancer by laterality, age, and race and ethnicity.Journal of the National Cancer Institute · 2025Article
- Clinical and sociodemographic risk factors associated with the development of second primary cancers among postmenopausal breast cancer survivors.Breast cancer (Tokyo, Japan) · 2023Article
- Risk, molecular subtype and prognosis of second primary breast cancer: an analysis based on first primary cancers.American journal of cancer research · 2023Article
- Clinical characteristics and survival of second primary breast carcinoma with extramammary malignancies.Frontiers in oncology · 2023Article
- The Pattern of Second Primary Tumours in Postmenopausal Women with Prior Breast Cancer in Western Romania: A Retrospective, Single-Institution Study.Diagnostics (Basel, Switzerland) · 2021Article
- Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.BMC cancer · 2021Article
- Research on Effectiveness of Prior Cancer on Survival Outcomes for Patients with Nonmetastatic Triple-Negative Breast Cancer: A Competing Risk Analysis and Propensity Score Matching Analysis of the SEER Database.Journal of oncology · 2021Article
- Exposure to Endocrine Disrupting Chemicals and Risk of Breast Cancer.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Second primary breast cancer (SPBC) is becoming one of the major obstacles to breast cancer (BC) control. This study was aimed to determine the trend of SPBC incidence over time and the risk of developing SPBC in site-specific primary cancer survivors in the United States. The Surveillance, Epidemiology, and End Results (SEER) 13 registry (1992-2015) was used to identify SPBC patients with previous malignancies. Standardized incidence ratio (SIR) was computed to compare the incidence rates of the observed cases of SPBC in cancer survivors over the expected cases in the general population. Elevated risk of SPBC was observed in women with previous BC (SIR = 1.74) or thyroid cancer (SIR = 1.17). Women with initial skin melanoma in older age (≥50 years) (SIR = 1.11), or White race (SIR = 1.11) presented an elevated incidence of SPBC than the general female population. Besides, Asian/Pacific Islander (API) women with cancer of corpus uteri, ovary, bladder, or kidney were prone to developing SPBC when compared with the general population, with SIRs of 1.61, 1.35, 1.48, and 1.70, respectively. Male BC patients showed profound risk of developing SPBC (SIR = 34.86). Male leukemia patients also presented elevated risk of developing SPBC (SIR = 2.06). Our study suggests significant increase of SPBC in both sexes in the United States. Elevated risk of SPBC exists in survivors with primary BC, female thyroid cancer, male leukemia, and API female cancer patients with primary genitourinary cancer. Our study is helpful in developing strategies for BC control and prevention on specific first primary cancer survivors with an elevated risk of SPBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.